BIOTECH & PHARMA

    Biotech and pharma stocks listed on the ASX.

    Immutep ASX IMM TACTI-mel Melanoma tumour shrinkage Phase I clinical study Keytruda metastatic melanoma

    Positive safety data reported from Immutep’s clinical trial to treat metastatic melanoma

    Admedus ASX AHZ sell CardioCel VascuCel patch LeMaitre Vascular

    Admedus agrees to sell CardioCel and VascuCel patch business to LeMaitre Vascular

    Dimerix ASX DXB DMX-700 Chronic Obstructive Pulmonary Disease COPD drug pipeline

    Dimerix targets ‘important new drug discovery’ in the treatment of chronic obstructive pulmonary disease

    Phylogica ASX PYC Therapeutics human retina in a dish model drug childhood blindness

    Phylogica achieves milestone in drug study aimed at treating childhood blindness

    Orthocell ASX OCC CelGro nerve regeneration quadriplegic patients

    Orthocell on course to revolutionise nerve regeneration after positive interim clinical results

    Clinuvel Pharmaceuticals ASX CUV FDA approval Scenesse genetic disorder US Food and Drug Administration

    Clinuvel Pharmaceuticals offers up novel drug to combat rare genetic disease following FDA approval

    Impression Healthcare IHL ASX cannabis Dr Sud Agarwal Incannex AGM presentationvideo

    Impression Healthcare AGM presentation from chief medical officer Dr Sud Agarwal

    Impression Healthcare ASX IHL cannabidiol head trauma

    Impression Healthcare files patent application for medicinal CBD drug to alleviate concussion injuries

    ResApp ASX RAP respiratory disease TGA approval paediatric treatments

    ResApp to take part in German digital health program, secures TGA approval

    Mayne Pharma ASX MYX Mithra Pharmaceuticals oral contraceptive Estetrol drospirenone

    Mayne Pharma and Mithra plan to introduce the ‘next generation’ oral contraceptive

    Immuron ASX IMC US Department of Defense funding Campylobacter

    US Department of Defense to fund Immuron in combatting gastrointestinal infections

    NeuroScientific Biopharmaceuticals ASX NSB Glaucoma EmtinB retina optic nerve

    NeuroScientific reveals positive results from pre-clinical glaucoma study

    Race Oncology ASX RAC Dr Daniel Tillett Chief Scientific Officer

    Race Oncology appoints biotech entrepreneur Dr Daniel Tillett as CSO

    Actinogen Medical ASX ACW cognitive improvement Xanamem XanaHES Alzheimer’s disease neurological

    Actinogen Medical announces ‘breakthrough’ study results for Alzheimer’s drug Xanamem

    Paradigm Biopharmaceuticals ASX PAR pentosan polysulfate sodium Zilosul PLOs One peer reviewed

    Paradigm Biopharmaceuticals looks to alleviate opiate crisis following ‘ground-breaking discovery

    Immutep ASX IMM Phase II clinical trial positive interim data immunotherapy cancer

    Immutep recruits more patients for non-small cell lung cancer trial, banks milestone payment from GlaxoSmithKline

    Bionomics ASX BNO PTSD drug BNC210 further clinical studies

    Bionomics’ PTSD drug on track for further clinical studies

    Osteopore ASX OSX IPO initial public offering implants bone healing biotech

    Osteopore makes ASX debut, plans to become leading producer of 3D-printed implants to promote bone regeneration

    Antisense Therapeutics ASX ANP Phase 2 clinical trial Duchenne Muscular Dystrophy DMD

    Antisense reports positive early results from clinical trial of new drug to treat patients with Duchenne muscular...

    Cynata Therapeutics ASX CYP Fujifilm graft-versus-host disease GvHD mesenchymal stem cell MSC CYP-001

    Fujifilm to commercialise Cynata Therapeutics’ mesenchymal stem cell technology

    Novita Healthcare ASX NHL Edtech Impact Tali Train

    Edtech Impact to market Novita Healthcare’s Tali Train product throughout UK schools

    Load more
    Small Caps ASX Australian stock market
    Small Caps is Australia's #1 site for market news & information on ASX listed small cap companies.

    Small Caps and affiliated companies accept no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. Small Caps or an associate may receive a commission for funds raised.
    Copyright 2019 Small Caps. All rights reserved.